Takeda Pharmaceutical Co Ltd (TKPHF) EBIT Margin (2017 - 2026)
Takeda Pharmaceutical (TKPHF) posted quarterly EBIT Margin of 16.51% for Q2 2026, down 17.0% year-over-year from 19.89% in Q2 2025, and little changed quarter-over-quarter from 16.51% in Q1 2026.
Takeda Pharmaceutical Co Ltd (TKPHF) EBIT Margin (2017 - 2026) Analysis & Trends
Takeda Pharmaceutical's EBIT Margin history runs 10 years deep, the most recent figure standing at 16.51% for Q2 2026.
- In Q2 2026, EBIT Margin fell 17.0% year-over-year to 16.51%; the TTM figure through Jun 2026 stood at 5.83% (down 455.0% YoY), while the FY2026 annual figure was 0.14%, down 734.0% from the prior year.
- EBIT Margin for Q2 2026 stood at 16.51%, roughly flat from 16.51% in the prior quarter.
- The five-year high for EBIT Margin was 25.56% in Q1 2022, with the low at 38.03% in Q4 2025.
- The 5-year median for EBIT Margin is 13.86% (2024), against an average of 10.5%.
- The sharpest annual moves came in 2022 and 2025: EBIT Margin jumped 602 bps in 2022, then plunged 3092 bps in 2025.
- Takeda Pharmaceutical's EBIT Margin stood at 13.4% in 2022, then tumbled by 37 bps to 8.43% in 2023, then slumped by 184 bps to 7.11% in 2024, then sank by 435 bps to 38.03% in 2025, then surged by 143 bps to 16.51% in 2026.
- Business Quant data shows TKPHF's EBIT Margin at 16.51% in Q2 2026, 16.51% in Q1 2026, and 38.03% in Q4 2025.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.51% |
| Mar 31, 2026 | 16.51% |
| Dec 31, 2025 | -38.03% |
| Sep 30, 2025 | 11.97% |
| Jun 30, 2025 | 16.68% |
| Mar 31, 2025 | 15.28% |
| Dec 31, 2024 | -7.11% |
| Sep 30, 2024 | 11.83% |
| Jun 30, 2024 | 13.77% |
| Mar 31, 2024 | 13.96% |
| Dec 31, 2023 | 8.43% |
| Sep 30, 2023 | 12.51% |
| Jun 30, 2023 | 15.92% |
| Mar 31, 2023 | 15.93% |
| Dec 31, 2022 | 13.40% |
| Sep 30, 2022 | 10.42% |
| Jun 30, 2022 | 15.48% |
| Mar 31, 2022 | 25.56% |
| Dec 31, 2021 | 12.92% |
| Sep 30, 2021 | 11.53% |